FK 506 Reverses Acute Graft-versus-host Disease After Allogeneic Bone Marrow Transplantation in Rats

Overview

Journal Surgery

Specialty General Surgery

Date 1991 Aug 1

PMID 1713358

Citations 7

Authors

P M Markus

X Cai

W Ming

A J Demetris

J J Fung

T E Starzl

Affiliations

Soon will be listed here.

Abstract

Severe graft-versus-host disease was induced by transplantation of ACI rat bone marrow and spleen cells into irradiated Lewis rat recipients. Treatment with FK 506 or cyclosporine A (CsA) was started after clinical and histologic evidence of acute GVHD was present. A 14-day course of FK 506 at 1.0 mg/kg/day could rescue 100% of the animals suffering from GVHD. In contrast only one half of the animals treated with CsA at a high dose of 25 mg/kg/day recovered. After cessation of immunosuppressive therapy, FK 506-treated animals displayed a marked prolonged disease-free interval as compared to CsA-treated bone marrow recipients. Recurrence of the disease in these animals could be prevented when FK 506 treatment was continued after the induction period with a low maintenance dose of 0.1 mg/kg/day every other day.

Citing Articles

Mouse models in bone marrow transplantation and adoptive cellular therapy.

Arber C, Brenner M, Reddy P Semin Hematol. 2013; 50(2):131-44.

PMID: 24216170 PMC: 3971726. DOI: 10.1053/j.seminhematol.2013.03.026.

Graft-versus-host disease after brown Norway-to-Lewis and Lewis-to-Brown Norway rat intestinal transplantation under FK506.

Murase N, Demetris A, Woo J, Tanabe M, Furuya T, Todo S Transplantation. 1993; 55(1):1-7.

PMID: 7678353 PMC: 2966149. DOI: 10.1097/00007890-199301000-00001.

The many faces of multivisceral transplantation.

Starzl T, Todo S, Tzakis A, Alessiani M, Casavilla A, Abu-Elmagd K Surg Gynecol Obstet. 1991; 172(5):335-44.

PMID: 2028370 PMC: 2655210.

Prevention of graft-versus-host disease following allogeneic bone marrow transplantation in rats using FK506.

Markus P, Cai X, Ming W, Demetris A, Fung J, Starzl T Transplantation. 1991; 52(4):590-4.

PMID: 1718063 PMC: 2975544. DOI: 10.1097/00007890-199110000-00002.

Graft-versus-host disease following liver transplantation.

Heaton N, Reece A, Tan K J R Soc Med. 1992; 85(6):313-4.

PMID: 1625257 PMC: 1293488.

References

Kino T, Hatanaka H, Miyata S, Inamura N, Nishiyama M, Yajima T . FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot (Tokyo). 1987; 40(9):1256-65. DOI: 10.7164/antibiotics.40.1256. View

Denham S, Attridge S, Barfoot R, Alexander P . Effect of cyclosporin A on the anti-leukaemia action associated with graft-versus-host disease. Br J Cancer. 1983; 47(6):791-5. PMC: 2011364. DOI: 10.1038/bjc.1983.132. View

Tutschka P, Beschorner W, Allison A, BURNS W, SANTOS G . Use of cyclosporin A in allogeneic bone marrow transplantation in the rat. Nature. 1979; 280(5718):148-51. DOI: 10.1038/280148a0. View

Siekierka J, Hung S, Poe M, Lin C, Sigal N . A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin. Nature. 1989; 341(6244):755-7. DOI: 10.1038/341755a0. View

Thomas E, Storb R, Clift R, Fefer A, Johnson L, Neiman P . Bone-marrow transplantation (second of two parts). N Engl J Med. 1975; 292(17):895-902. DOI: 10.1056/NEJM197504242921706. View

Storb R, Thomas E . Allogeneic bone-marrow transplantation. Immunol Rev. 1983; 71:77-102. DOI: 10.1111/j.1600-065x.1983.tb01069.x. View

Gill 3rd T, Kunz H, Misra D, Hassett A . The major histocompatibility complex of the rat. Transplantation. 1987; 43(6):773-85. View

Thomson A, Whiting P, Blair J, Davidson R, Simpson J . Pathological changes developing in the rat during a 3-week course of high dosage cyclosporin A and their reversal following drug withdrawal. Transplantation. 1981; 32(4):271-7. DOI: 10.1097/00007890-198110000-00002. View

Todo S, Ueda Y, Demetris J, Imventarza O, Nalesnik M, Venkataramanan R . Immunosuppression of canine, monkey, and baboon allografts by FK 506: with special reference to synergism with other drugs and to tolerance induction. Surgery. 1988; 104(2):239-49. PMC: 2972580. View

10.

Ochiai T, Nakajima K, Nagata M, Hori S, Asano T, Isono K . Studies of the induction and maintenance of long-term graft acceptance by treatment with FK506 in heterotopic cardiac allotransplantation in rats. Transplantation. 1987; 44(6):734-8. DOI: 10.1097/00007890-198712000-00002. View

11.

Remlinger K, Martin P, Hansen J, Doney K, Smith A, Deeg H . Murine monoclonal anti-T cell antibodies for treatment of steroid-resistant acute graft-versus-host disease. Hum Immunol. 1984; 9(1):21-35. DOI: 10.1016/0198-8859(84)90004-1. View

12.

Beschorner W, Tutschka P, SANTOS G . Sequential morphology of graft-versus-host disease in the rat radiation chimera. Clin Immunol Immunopathol. 1982; 22(2):203-24. PMC: 7133186. DOI: 10.1016/0090-1229(82)90038-1. View

13.

Markus P, Cai X, Ming W, Demetris A, Fung J, Starzl T . Prevention of graft-versus-host disease following allogeneic bone marrow transplantation in rats using FK506. Transplantation. 1991; 52(4):590-4. PMC: 2975544. DOI: 10.1097/00007890-199110000-00002. View

14.

Harding M, Galat A, Uehling D, Schreiber S . A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase. Nature. 1989; 341(6244):758-60. DOI: 10.1038/341758a0. View

15.

Powles R, Barrett A, Clink H, Kay H, Sloane J, McElwain T . Cyclosporin A for the treatment of graft-versus-host disease in man. Lancet. 1978; 2(8104-5):1327-31. DOI: 10.1016/s0140-6736(78)91971-2. View

16.

Starzl T, Todo S, Fung J, Demetris A, Venkataramman R, Jain A . FK 506 for liver, kidney, and pancreas transplantation. Lancet. 1989; 2(8670):1000-4. PMC: 2966318. DOI: 10.1016/s0140-6736(89)91014-3. View

17.

Sullivan K, Deeg H, Sanders J, Klosterman A, Amos D, Shulman H . Hyperacute graft-v-host disease in patients not given immunosuppression after allogeneic marrow transplantation. Blood. 1986; 67(4):1172-5. View

18.

Deeg H, Henslee-Downey P . Management of acute graft-versus-host disease. Bone Marrow Transplant. 1990; 6(1):1-8. View

19.

Fung J, Todo S, Tzakis A, Demetris A, Jain A, Alessiani M . Conversion of liver allograft recipients from cyclosporine to FK 506-based immunosuppression: benefits and pitfalls. Transplant Proc. 1991; 23(1 Pt 1):14-21. PMC: 2954599. View

20.

Todo S, Fung J, Starzl T, Tzakis A, Demetris A, Kormos R . Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg. 1990; 212(3):295-305; discussion 306-7. PMC: 1358160. DOI: 10.1097/00000658-199009000-00008. View